Home >> Research >> Inflammation, Immunity & Immunotherapeutics Theme

Inflammation, Immunity & Immunotherapeutics Theme

Our Inflammation, Immunity & Immunotherapeutics Theme has 5 priority areas:

  • fibrosis and inflammation therapies
  • gene and cell therapy
  • new therapies for inflammatory arthritis-rheumatology
  • infectious diseases prediction and stratification
  • novel therapies for protein folding disorders.

Experimental medicine research across these priority areas focuses on identifying biomarkers for disease, developing innovative diagnostic and therapeutic tools for disease detection, and the treatment and stratification of patients.

Lay panel

To encourage patients and the public to get actively involved in our research and to support researchers in involving lay people, we have a patient panel. This panel looks at research proposals and study documentation and advises researchers. If you are a lay person and would like to join the panel please contact Saadia Rahman saadia.rahman@ucl.ac.uk tel: 020 7679 2425. 

If you are a researcher and would like to use this resource please note the panel meets regularly to review study documentation before it is submitted for ethics review, or as part of a grant application. The panel is also able to email feedback on proposals or study documentation. Feedback will be provided to the investigator within 2 weeks of review. If you would like to make use of this resource, please contact Saadia Rahman saadia.rahman@ucl.ac.uk tel: 020 3447 5969 to discuss your needs. As well as study documentation such as consent forms for review, we will need a summary of the research proposal written in lay language in addition.

Partnership working

Investigators from the III Programme are partners in both of the NIHR Office for Clinical Research Infrastructure (NOCRI) Translational Research Partnerships:

  • Joint and Related Inflammatory Diseases  - Centre Academic Lead (CAL) Professor David Isenberg
  • Inflammatory Respiratory - CAL Dr Jo Porter

Nandi Simpson is the Centre Business Lead for the partnerships. 

See the NIHR Translational Research Partnerships webpage.

Support from our programme links the NIHR University College London Hospitals BRC to the NIHR Great Ormond Street BRC via the Arthritis Research UK Centre for Adolescent Rheumatology, and NIHR Guy's and St Thomas's BRC via the Wolfson Gene Therapy Unit.

III Programme investigators in infection are at the core of the Bloomsbury Research Institute, a major collaborative initiative with the London School of Hygiene & Tropical Medicine. The Programme also supports the Wolfson Drug Discovery Unit, part of the world-leading Centre for Amyloidosis and Acute Phase Proteins.

Our programme is leading on two Bioresource initiatives:

  • The HIV Bioresource linked to the UK Collaborative HIC Cohort Study (UK CHIC) 
  • BioAID, a multicentre transcriptome profiling project linking UCLH/UCL, Imperial-Hammersmith, Imperial-St Marys, GSTT/KCL, Cambridge University Hospitals NHS Trust-Addenbrookes and Oxford University Hospitals NHS Trust-John Radcliffe Hospital

Major grants

  • Over the last year, investigators from this programme have received two EU FP7- Health grants for research with a focus on diagnostics. These awards totalling more than €15 million will support the development of rapid identification of respiratory tract infections (RidRTI), and development of automated next generation sequencing techniques for diagnostic microbiology (PATHSEEK).
  • EUFP7 funding of €6 million was also secured for the EVERREST project to study fetal growth restriction. Click here to go to the EVERREST website.
  • A Health Innovation Challenge Fund award of £3.4 million was secured for the ICONIC project, which will use viral whole genome sequencing to guide stratified patient management, infection control and national surveillance. In collaboration with partners Wellcome Trust Sanger Institute, Health Protection England, NHS trusts, MRC CTU and The Doctors Laboratory, ICONIC will link full length viral sequences to clinical data. 
  • Investigators with industry partners OJ-Bio were awarded £800K via the NIHR i4i stream to develop a new hand-held device for the rapid diagnosis of patients at the early stages of HIV. Further to this, £11m from the Engineering and Physical Sciences Research Council has been awarded for an Interdisciplinary Research Collaboration (IRC) led by UCL and involving BRC investigators. The IRC will develop early-warning sensor systems that can test and track serious infectious disease - such as major flu epidemics, MRSA and HIV - using mobile phones and the internet. Click here to read the full news story.
  • The Wolfson Drug Discovery Unit has received substantial research grants totalling more than £7 million, comprising two MRC Developmental Clinical Studies Scheme awards, MRC Research Grants and a British Heart Foundation Special Project Grant.  The research capacity of the Unit is crucially underpinned by core support from the BRC III and Cardiometabolic Programmes
  • More than £600K was received from Arthritis Research UK for the first UK Centre for Adolescent Rheumatology Research, which was launched in November 2012.

Funding

The III programme supports novel and impactful research specific to experimental medicine. See the latest funding awards from September 2014 here.

 

Adolescent rheumatology research